Dr. Chen (Cheney) Mao has over 20 years of experience in the industry. Dr. Mao obtained his bachelor’s and master’s degree from Fudan University in the PRC, and obtained his Ph.D. degree in biochemistry from Cornell University in the U.S. After graduation, he served as a director of the Department of Structural Biology of Parker Hughes Institute.
He also served as a reviewer on the U.S. National Institutes of Health Review Panel ZRG1 AARR-1(50) in relation to AIDS-related structural biology projects grants.
Dr. David Xu has over 20 years of pharma experiences in drug development, sales and marketing. He is responsible for the investment and incubation business at Viva Biotech.
Dr. Xu started his career at Novartis (US) and held various positions in Development and Commercial, including Head of Specialty Products Franchise at SANDOZ, Inc. and Head of Suzhou Novartis R&D center.
Dr. Xu was Head of Marketing and New Product Planning at Purdue Pharma(US) before joining Viva.
Cathy He received her MBA degree from University of Chicago and is an experienced investment professional, strategist. She has over 10 years of investment experience on Wall Street, in private equity, and mutual fund. Professional expertise includes public and private investment management, board member of biopharma companies, quantitative modeling, stock valuation and selection, deal and term sheet negotiation.
She has previously held various positions at Lehman Brothers, Bank of America and Wellington Management.
Yinghong is currently an Associate Business Partner at Viva Biotech & Venture and the VP of Business Development for Viva’s CRO business. She has broad business development experience ranging from early drug discovery to pre-clinical and clinical development. Prior to that, she was an integral team member of target selection, licensing & scientific network of MerckMillipore, responsible for lead evaluation and new product introduction.
She started her drug discovery career as a medicinal chemist with additional expertise in computer aided drug design, working at biotech companies including Cytel Corporation, Neurocrine Biosciences and Arena Pharmaceuticals with increasing responsibilities. Her successful drug discovery track record is evidenced by over 30 publications and patents, multiple IND clinical candidates in different therapeutic areas and her indelible contributions to the discovery of Elagolix which led to the successful partnership with AbbVie and the recent FDA approval in 2018. She holds a MSc. Degree from Chinese Academy of Sciences in physical chemistry and a MSc. Degree from Tulane University in organic chemistry.
Dr. Cynthia Cai is an executive and investor with over twenty-five years of experience in healthcare and life science industry. International experience in sales, marketing, business development, and equity investment.
Prior to join Viva, Dr. Cai was senior director of global marketing in Agilent Technologies, and senior advisor for Northen Light Venture Captial. Dr. Cai earned a B.A. and Master of Engineering from Tsinghua University, received her Ph.D. in Chemistry from the University of Massachusetts, and MBA from The Wharton Business School of the University of Pennsylvania.